drugset / Trial / NCT07065630

Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

NCT07065630

Phase 2 Recruiting 38 enrolled University of Chicago
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to assess the objective response rate following neoadjuvant therapy with volrustomig, paclitaxel, and carboplatin in previously untreated human papillomavirus (HPV)-negative locally advanced head and neck squamous cell carcinoma .

Timeline

Start
2025-10-07
Primary completion
2029-08-13
Completion
2029-08-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 5 unknown Intravenous
Subject Paclitaxel Small molecule 100 mg/m2 Intravenous
Subject Volrustomig Monoclonal antibody 250 mg Intravenous